Similarly, strategies for tumor-localized Piezo1 targeting via nanoparticle-mediated local delivery aim to enhance NK function while minimizing off-target activation in endothelial cells or erythrocytes, yet pharmacokinetic, biodistribution, and toxicity profiles for such approaches are currently lacking. This evidence concerns the gene PIEZO1 and neoplasm.